Category: Approval/Launch Region: Europe · United Kingdom Company: Astrazeneca Ltd

EU approves AstraZeneca and MSDs Lynparza as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

EU approves AstraZeneca and MSDs Lynparza as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
AstraZeneca and MSD

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!